Aesculap recently launched its M.blue hydrocephalus valve. The valve is adjustable gravitational valve that features an integrated fixed pressure differential valve during the most active time of the day, according to the company. The fixed pressure differential valve addresses posture changes. “We are very pleased to be able to continue to provide healthcare teams with […]
B. Braun’s Aesculap closes $17m Dextera Surgical bankruptcy buyout
Surgical instrument maker Dextera Surgical and B. Braun subsidiary Aesculap said yesterday that they closed the $17.3 million deal to buy Dextera out of Chapter 11 bankruptcy. Redwood City, Calif.- based Dextera, formerly known as Cardica, agreed to the buyout in December 2017. The consummation Feb. 20 saw Dextera receive $13.6 million; another $2 million went into two-year escrow, $900,000 went to repay […]
7 medtech stories we missed this week: April 7, 2017
New studies for umbilical cord allografts and tumor targeting were published this week while another company received European CE Marking. Here are some medtech stories we missed this week but thought were still worth mentioning. 1. AMNIOX touts new umbilical cord study AMNIOX Medical announced that it has published the results of 3 studies that demonstrate […]
B. Braun’s Aesculap wins FDA nod for lumbar disc
B. Braun Medical subsidiary Aesculap said today that it won FDA approval for its ActivL artificial disc indicated for the treatment of 1-level lumbar degenerative disc disease. The ActivL is designed as an alternative to spinal fusion surgery, the Center Valley, Pa.-based company said, and is the 1st lumbar disc with a mobile ultra high molecular […]
Teleflex affirms 2012 guidance | Wall Street Beat
Teleflex (NYSE:TFX) said yesterday that it expects its 2012 earnings to meet Wall Street’s expectations, but forecast softer profits for the coming year.
The Limerick, Pa.-based medical device company said its "preliminary financial goals" for 2013 are for sales growth of 11%-13% and adjusted EPS of $4.70-$4.90.
Olympus board resigns en masse | Wall Street Beat
The new slate of directors for Olympus Corp. (TYO:7733) is already drawing fire from foreign investors in the endoscopy giant, after its entire board resigned en masse over a $1.7 billion accounting scandal that’s slashed its valuation by about 50% since October.
GPOs: Premier, Child Health Corp. ink new deals
Group purchasing organization Premier said it signed a raft of supply deals for a variety of medical device products.
The Charlotte-based GPO said it signed deals for endomechanical, trocar, suture and topical skin adhesives with 16 companies.
B. Braun’s surgical instruments maker Aesculap nabs Aragon’s electrosurgical devices
Veteran surgical devices maker and B. Braun Medical Inc. subsidiary Aesculap Inc. snapped up Aragon Surgical Inc. and its radiofrequency electrosurgical instruments for tissue fusion and cutting.
Aragon’s Caiman instruments are the only radiofrequency devices on the market with an articulating end to allow surgeons more maneuverability with tissue fusion and cutting during surgery.
Aesculap acquires Aragon’s electrosurgical devices
Aesculap, Inc. Acquires Aragon Surgical, Inc.
Misonix spikes distribution deal with Aesculap
Misonix Inc. (NSDQ:MSON) spiked a U.S. distribution deal with Aesculap Inc. for its SonaStar surgical aspiration system, saying it will sell the device direct through its own sales operation.
The new arrangement becomes effective Oct. 18.
Misonix said it will use its 75-person sales force to market the device, which is used to remove hard and soft tumors during neurological and general surgeries.
Aesculap wins 510(k) for spinal fusion device
The Food & Drug Administration cleared Aesculap Implant Systems LLC’s S4 cervical occipital plating system.
The Center Valley, Pa.-based company received a "substantial equivalence" determination for its Special 510(k) application for the spinal injury treatment system seven months after the FDA began its review of the device, according to the company.
